Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Articles

Jaypirca (pirtobrutinib) has received a conditional marketing authorization from EMA for mantle cell lymphoma. The drug was approved in the United States in 2023 for several indications.

EMA Gives Positive Opinion to Lilly Treatment for Chronic Lymphocytic Leukemia

More than 6000 rare diseases—those which affect fewer than one in 2000 people each—are acknowledged in the medical community, with 72% of them being genetic.

Rare Disease Day Celebrated on February 28

Regulatory clearances and approvals continue as agencies work to disseminate literature, raise awareness, redouble research efforts, and improve the efficacy of clinical trials.

Rare Disease Day 2025: Pharmaceutical Treatments Advancing in the US, EU

Webcasts

Webinar Date/Time: Fri, Mar 21, 2025 11:00 AM EDT

Strategic Partnerships

While the boards of directors of both companies have approved the transaction, it is not expected to close until the second quarter of 2025, as Mayne Pharma’s shareholders must still vote in favor of the acquisition.

Cosette Pharmaceuticals Adds to Dermatology and Women’s Health Portfolio with Mayne Pharma Purchase

Feliza Mirasol is the science editor for 

The value of outsourcing partnerships for next-gen biotherapeutics rests in the expertise and technologies that service providers bring to the table.

Outsourcing Next-Gen Therapies Relies on Expertise and Technology

Webinar Date/Time: Thu, Mar 13, 2025 11:00 AM EDT

 Powering Clinical Operations With Knowledge Graphs and LLMs With Merck KGaA, Darmstadt, Germany

The collaboration will utilize Genesis’ proprietary AI platform, initially focusing on targets selected by Incyte.

Incyte, Genesis Therapeutics to Use AI Platform to Discover Small Molecule Compounds

A capsule formulation may offer more consistent and reliable uptake versus a syringe, while being less dependent on food intake.

DSM-Firmenich CBD Product Shows Promise in OSD Forms, Study Says

The AI co-scientist is a multi-agent AI system that can work as a virtual scientific collaborator.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development